David Meeker adds another biotech board spot to the post-Genzyme resume; J&J’s DePuy acquires 3D printing tech for bone healing
→ Soon-to-be-ex-Genzyme head David Meeker has added another biotech board position to his resume. Just a few days after being named chairman at Rhythm, South San Francisco-based MyoKardia has named Meeker to the board. Meeker will be leaving Genzyme after a long career in June.
→ J&J’s DePuy Synthes Products has acquired 3D printing technology from Tissue Regeneration Systems. DePuy plans to use the technology to “create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopedic and craniomaxillofacial deformities and injuries.” Financial terms of the transaction have not been disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.